Vifor Pharma’s hypertension and CKD drug Veltassa meets primary endpoint in phase II study

Vifor Pharma’s hypertension and CKD drug Veltassa meets primary endpoint in phase II study

Submitted by admin on May 13, 2019 - 9:25am
Source: 
Pharmaceutical Business Review
News Tags: 
Vifor
hypertension
chronic kidney disease
Veltassa
clinical trials
Headline: 
Vifor Pharma’s hypertension and CKD drug Veltassa meets primary endpoint in phase II study
snippet: 

Vifor Pharma announced that its hypertension and chronic kidney disease (CKD) drug Veltassa (patiromer) has met its primary endpoint in phase II Amber study.

Do Not Allow Advertisers to Use My Personal information